nodes	percent_of_prediction	percent_of_DWPC	metapath
Dronabinol—CYP1A1—Clobetasol propionate—psoriasis	0.123	0.153	CbGbCtD
Dronabinol—CYP2A6—Methoxsalen—psoriasis	0.0753	0.094	CbGbCtD
Dronabinol—CYP1A1—Methoxsalen—psoriasis	0.0644	0.0804	CbGbCtD
Dronabinol—CYP1A1—Cholecalciferol—psoriasis	0.0426	0.0532	CbGbCtD
Dronabinol—ABCG2—Mycophenolate mofetil—psoriasis	0.04	0.05	CbGbCtD
Dronabinol—CYP2A6—Prednisolone—psoriasis	0.0366	0.0457	CbGbCtD
Dronabinol—ABCG2—Hydrocortisone—psoriasis	0.0321	0.0401	CbGbCtD
Dronabinol—ABCG2—Cyclosporine—psoriasis	0.0303	0.0379	CbGbCtD
Dronabinol—CYP2A6—Dexamethasone—psoriasis	0.0216	0.027	CbGbCtD
Dronabinol—CYP2C19—Cholecalciferol—psoriasis	0.0206	0.0258	CbGbCtD
Dronabinol—ABCG2—Dexamethasone—psoriasis	0.02	0.025	CbGbCtD
Dronabinol—CYP3A4—Calcitriol—psoriasis	0.0194	0.0242	CbGbCtD
Dronabinol—CYP1A1—Dexamethasone—psoriasis	0.0184	0.023	CbGbCtD
Dronabinol—CYP2C9—Cholecalciferol—psoriasis	0.0172	0.0214	CbGbCtD
Dronabinol—ABCG2—Methotrexate—psoriasis	0.0161	0.0201	CbGbCtD
Dronabinol—CYP3A4—Methoxsalen—psoriasis	0.0151	0.0188	CbGbCtD
Dronabinol—ABCB1—Mycophenolate mofetil—psoriasis	0.0144	0.018	CbGbCtD
Dronabinol—CYP2C19—Prednisone—psoriasis	0.0143	0.0179	CbGbCtD
Dronabinol—CYP2C19—Cyclosporine—psoriasis	0.0136	0.0169	CbGbCtD
Dronabinol—ABCB1—Betamethasone—psoriasis	0.0124	0.0155	CbGbCtD
Dronabinol—ABCB1—Prednisolone—psoriasis	0.0122	0.0153	CbGbCtD
Dronabinol—ABCB1—Hydrocortisone—psoriasis	0.0116	0.0145	CbGbCtD
Dronabinol—ABCB1—Prednisone—psoriasis	0.0115	0.0144	CbGbCtD
Dronabinol—CYP2C9—Cyclosporine—psoriasis	0.0113	0.0141	CbGbCtD
Dronabinol—ABCB1—Cyclosporine—psoriasis	0.0109	0.0137	CbGbCtD
Dronabinol—CYP3A4—Cholecalciferol—psoriasis	0.00998	0.0125	CbGbCtD
Dronabinol—CYP2C19—Dexamethasone—psoriasis	0.00893	0.0112	CbGbCtD
Dronabinol—CYP3A4—Mycophenolate mofetil—psoriasis	0.00865	0.0108	CbGbCtD
Dronabinol—CYP3A4—Triamcinolone—psoriasis	0.00865	0.0108	CbGbCtD
Dronabinol—CYP2C9—Dexamethasone—psoriasis	0.00743	0.00927	CbGbCtD
Dronabinol—CYP3A4—Betamethasone—psoriasis	0.00742	0.00927	CbGbCtD
Dronabinol—CYP3A4—Prednisolone—psoriasis	0.00732	0.00914	CbGbCtD
Dronabinol—ABCB1—Dexamethasone—psoriasis	0.00721	0.009	CbGbCtD
Dronabinol—CYP3A4—Hydrocortisone—psoriasis	0.00694	0.00867	CbGbCtD
Dronabinol—CYP3A4—Prednisone—psoriasis	0.00692	0.00864	CbGbCtD
Dronabinol—CYP3A4—Cyclosporine—psoriasis	0.00656	0.00819	CbGbCtD
Dronabinol—ABCB1—Methotrexate—psoriasis	0.00579	0.00723	CbGbCtD
Dronabinol—CYP3A4—Dexamethasone—psoriasis	0.00432	0.00539	CbGbCtD
Dronabinol—CYP2A6—CYP2E1 reactions—CYP2S1—psoriasis	0.00288	0.0577	CbGpPWpGaD
Dronabinol—CYP2A6—Xenobiotics—CYP2S1—psoriasis	0.00178	0.0358	CbGpPWpGaD
Dronabinol—CYP2C19—CYP2E1 reactions—CYP2S1—psoriasis	0.00175	0.0352	CbGpPWpGaD
Dronabinol—CYP2C9—CYP2E1 reactions—CYP2S1—psoriasis	0.0016	0.0321	CbGpPWpGaD
Dronabinol—CYP1A1—Xenobiotics—CYP2S1—psoriasis	0.00133	0.0266	CbGpPWpGaD
Dronabinol—CNR2—G alpha (i) signalling events—HCAR2—psoriasis	0.0012	0.0242	CbGpPWpGaD
Dronabinol—CYP2C19—Xenobiotics—CYP2S1—psoriasis	0.00109	0.0218	CbGpPWpGaD
Dronabinol—CYP2C9—Xenobiotics—CYP2S1—psoriasis	0.000992	0.0199	CbGpPWpGaD
Dronabinol—CNR2—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000958	0.0192	CbGpPWpGaD
Dronabinol—CNR1—G alpha (i) signalling events—HCAR2—psoriasis	0.000946	0.019	CbGpPWpGaD
Dronabinol—ABCB1—Allograft Rejection—IL22—psoriasis	0.000852	0.0171	CbGpPWpGaD
Dronabinol—CNR1—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000752	0.0151	CbGpPWpGaD
Dronabinol—CYP2A6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000741	0.0149	CbGpPWpGaD
Dronabinol—CYP2A6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000731	0.0147	CbGpPWpGaD
Dronabinol—CNR2—GPCR ligand binding—HCAR2—psoriasis	0.00073	0.0146	CbGpPWpGaD
Dronabinol—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.000654	0.0131	CbGpPWpGaD
Dronabinol—PTGS1—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000635	0.0127	CbGpPWpGaD
Dronabinol—CNR2—G alpha (i) signalling events—CCL20—psoriasis	0.000626	0.0125	CbGpPWpGaD
Dronabinol—CYP2A6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000601	0.012	CbGpPWpGaD
Dronabinol—CNR1—GPCR ligand binding—HCAR2—psoriasis	0.000572	0.0115	CbGpPWpGaD
Dronabinol—CYP1A1—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000552	0.0111	CbGpPWpGaD
Dronabinol—ABCG2—Iron uptake and transport—CP—psoriasis	0.000545	0.0109	CbGpPWpGaD
Dronabinol—CYP1A1—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000545	0.0109	CbGpPWpGaD
Dronabinol—CNR2—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000498	0.00997	CbGpPWpGaD
Dronabinol—CNR1—G alpha (i) signalling events—CCL20—psoriasis	0.000491	0.00984	CbGpPWpGaD
Dronabinol—PTGS1—Overview of nanoparticle effects—CRP—psoriasis	0.000469	0.0094	CbGpPWpGaD
Dronabinol—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKBIA—psoriasis	0.000464	0.0093	CbGpPWpGaD
Dronabinol—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000452	0.00905	CbGpPWpGaD
Dronabinol—CYP1A1—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000447	0.00897	CbGpPWpGaD
Dronabinol—CYP2C19—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000446	0.00894	CbGpPWpGaD
Dronabinol—CNR2—GPCR downstream signaling—HCAR2—psoriasis	0.000412	0.00826	CbGpPWpGaD
Dronabinol—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000412	0.00826	CbGpPWpGaD
Dronabinol—CYP2C9—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000406	0.00815	CbGpPWpGaD
Dronabinol—CNR1—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.00039	0.00783	CbGpPWpGaD
Dronabinol—ABCG2—HIF-1-alpha transcription factor network—CP—psoriasis	0.000387	0.00775	CbGpPWpGaD
Dronabinol—CNR2—GPCR ligand binding—CCL20—psoriasis	0.000379	0.0076	CbGpPWpGaD
Dronabinol—CNR2—Signaling by GPCR—HCAR2—psoriasis	0.000374	0.0075	CbGpPWpGaD
Dronabinol—CYP2C19—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000366	0.00734	CbGpPWpGaD
Dronabinol—ABCB1—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000353	0.00707	CbGpPWpGaD
Dronabinol—PTGS1—Biological oxidations—CYP2S1—psoriasis	0.000337	0.00676	CbGpPWpGaD
Dronabinol—CYP2C9—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000334	0.00669	CbGpPWpGaD
Dronabinol—CNR1—GPCR downstream signaling—HCAR2—psoriasis	0.000324	0.00648	CbGpPWpGaD
Dronabinol—CYP2A6—Biological oxidations—CYP2S1—psoriasis	0.000319	0.00639	CbGpPWpGaD
Dronabinol—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—JUN—psoriasis	0.000308	0.00616	CbGpPWpGaD
Dronabinol—PTGS1—Overview of nanoparticle effects—CXCL8—psoriasis	0.000305	0.00611	CbGpPWpGaD
Dronabinol—CNR1—GPCR ligand binding—CCL20—psoriasis	0.000297	0.00596	CbGpPWpGaD
Dronabinol—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKB1—psoriasis	0.000296	0.00593	CbGpPWpGaD
Dronabinol—CNR1—Signaling by GPCR—HCAR2—psoriasis	0.000294	0.00589	CbGpPWpGaD
Dronabinol—CYP1A1—Oxidative Stress—CAT—psoriasis	0.000289	0.00579	CbGpPWpGaD
Dronabinol—CNR1—BDNF signaling pathway—NFKBIA—psoriasis	0.000275	0.00552	CbGpPWpGaD
Dronabinol—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000272	0.00544	CbGpPWpGaD
Dronabinol—CYP1A1—Estrogen Receptor Pathway—JUN—psoriasis	0.000271	0.00542	CbGpPWpGaD
Dronabinol—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—psoriasis	0.000269	0.00539	CbGpPWpGaD
Dronabinol—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000268	0.00537	CbGpPWpGaD
Dronabinol—Hypersensitivity—Hydroxyurea—psoriasis	0.000265	0.00178	CcSEcCtD
Dronabinol—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	0.000265	0.00531	CbGpPWpGaD
Dronabinol—Malaise—Mycophenolate mofetil—psoriasis	0.000263	0.00176	CcSEcCtD
Dronabinol—Decreased appetite—Mycophenolic acid—psoriasis	0.000262	0.00176	CcSEcCtD
Dronabinol—Cough—Cyclosporine—psoriasis	0.000261	0.00175	CcSEcCtD
Dronabinol—Fatigue—Mycophenolic acid—psoriasis	0.00026	0.00174	CcSEcCtD
Dronabinol—Hallucination—Dexamethasone—psoriasis	0.00026	0.00174	CcSEcCtD
Dronabinol—Hallucination—Betamethasone—psoriasis	0.00026	0.00174	CcSEcCtD
Dronabinol—Convulsion—Cyclosporine—psoriasis	0.000259	0.00174	CcSEcCtD
Dronabinol—Asthenia—Hydroxyurea—psoriasis	0.000259	0.00173	CcSEcCtD
Dronabinol—Ataxia—Methotrexate—psoriasis	0.000258	0.00173	CcSEcCtD
Dronabinol—Palpitations—Mycophenolate mofetil—psoriasis	0.000258	0.00173	CcSEcCtD
Dronabinol—Myalgia—Cyclosporine—psoriasis	0.000255	0.00171	CcSEcCtD
Dronabinol—Cough—Mycophenolate mofetil—psoriasis	0.000255	0.00171	CcSEcCtD
Dronabinol—Anxiety—Cyclosporine—psoriasis	0.000254	0.0017	CcSEcCtD
Dronabinol—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—psoriasis	0.000253	0.0017	CcSEcCtD
Dronabinol—Convulsion—Mycophenolate mofetil—psoriasis	0.000253	0.00169	CcSEcCtD
Dronabinol—Ill-defined disorder—Prednisolone—psoriasis	0.000253	0.00169	CcSEcCtD
Dronabinol—Depression—Prednisone—psoriasis	0.000252	0.00169	CcSEcCtD
Dronabinol—Discomfort—Cyclosporine—psoriasis	0.000252	0.00169	CcSEcCtD
Dronabinol—Dry mouth—Cyclosporine—psoriasis	0.000249	0.00167	CcSEcCtD
Dronabinol—Feeling abnormal—Mycophenolic acid—psoriasis	0.000249	0.00167	CcSEcCtD
Dronabinol—Myalgia—Mycophenolate mofetil—psoriasis	0.000248	0.00167	CcSEcCtD
Dronabinol—Anxiety—Mycophenolate mofetil—psoriasis	0.000248	0.00166	CcSEcCtD
Dronabinol—Gastrointestinal pain—Mycophenolic acid—psoriasis	0.000247	0.00165	CcSEcCtD
Dronabinol—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—psoriasis	0.000247	0.00165	CcSEcCtD
Dronabinol—Ill-defined disorder—Hydrocortisone—psoriasis	0.000247	0.00165	CcSEcCtD
Dronabinol—Diarrhoea—Hydroxyurea—psoriasis	0.000247	0.00165	CcSEcCtD
Dronabinol—Confusional state—Cyclosporine—psoriasis	0.000246	0.00165	CcSEcCtD
Dronabinol—Malaise—Prednisolone—psoriasis	0.000245	0.00165	CcSEcCtD
Dronabinol—Discomfort—Mycophenolate mofetil—psoriasis	0.000245	0.00165	CcSEcCtD
Dronabinol—Dry mouth—Mycophenolate mofetil—psoriasis	0.000243	0.00163	CcSEcCtD
Dronabinol—Confusional state—Mycophenolate mofetil—psoriasis	0.00024	0.00161	CcSEcCtD
Dronabinol—Malaise—Hydrocortisone—psoriasis	0.00024	0.00161	CcSEcCtD
Dronabinol—Nervous system disorder—Cyclosporine—psoriasis	0.000239	0.00161	CcSEcCtD
Dronabinol—Abdominal pain—Mycophenolic acid—psoriasis	0.000239	0.0016	CcSEcCtD
Dronabinol—Dizziness—Hydroxyurea—psoriasis	0.000238	0.0016	CcSEcCtD
Dronabinol—CYP1A1—Biological oxidations—CYP2S1—psoriasis	0.000238	0.00476	CbGpPWpGaD
Dronabinol—Skin disorder—Cyclosporine—psoriasis	0.000237	0.00159	CcSEcCtD
Dronabinol—Hyperhidrosis—Cyclosporine—psoriasis	0.000236	0.00158	CcSEcCtD
Dronabinol—Convulsion—Prednisolone—psoriasis	0.000236	0.00158	CcSEcCtD
Dronabinol—CYP1A1—Metapathway biotransformation—CYP2S1—psoriasis	0.000234	0.0047	CbGpPWpGaD
Dronabinol—CYP1A1—Estrogen Receptor Pathway—STAT3—psoriasis	0.000234	0.00469	CbGpPWpGaD
Dronabinol—Nervous system disorder—Mycophenolate mofetil—psoriasis	0.000234	0.00157	CcSEcCtD
Dronabinol—Anorexia—Cyclosporine—psoriasis	0.000233	0.00156	CcSEcCtD
Dronabinol—Tachycardia—Mycophenolate mofetil—psoriasis	0.000232	0.00156	CcSEcCtD
Dronabinol—Ill-defined disorder—Triamcinolone—psoriasis	0.000232	0.00156	CcSEcCtD
Dronabinol—Skin disorder—Mycophenolate mofetil—psoriasis	0.000231	0.00155	CcSEcCtD
Dronabinol—CYP1A1—Melatonin metabolism and effects—APOE—psoriasis	0.00023	0.00462	CbGpPWpGaD
Dronabinol—Convulsion—Hydrocortisone—psoriasis	0.00023	0.00154	CcSEcCtD
Dronabinol—Hyperhidrosis—Mycophenolate mofetil—psoriasis	0.00023	0.00154	CcSEcCtD
Dronabinol—Discomfort—Prednisolone—psoriasis	0.000229	0.00153	CcSEcCtD
Dronabinol—Rash—Hydroxyurea—psoriasis	0.000227	0.00152	CcSEcCtD
Dronabinol—Anorexia—Mycophenolate mofetil—psoriasis	0.000227	0.00152	CcSEcCtD
Dronabinol—Dermatitis—Hydroxyurea—psoriasis	0.000227	0.00152	CcSEcCtD
Dronabinol—Myalgia—Hydrocortisone—psoriasis	0.000226	0.00152	CcSEcCtD
Dronabinol—Hallucination—Prednisone—psoriasis	0.000226	0.00152	CcSEcCtD
Dronabinol—Malaise—Triamcinolone—psoriasis	0.000226	0.00151	CcSEcCtD
Dronabinol—Headache—Hydroxyurea—psoriasis	0.000226	0.00151	CcSEcCtD
Dronabinol—Anxiety—Hydrocortisone—psoriasis	0.000226	0.00151	CcSEcCtD
Dronabinol—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—psoriasis	0.000225	0.00151	CcSEcCtD
Dronabinol—Discomfort—Hydrocortisone—psoriasis	0.000224	0.0015	CcSEcCtD
Dronabinol—Hypotension—Mycophenolate mofetil—psoriasis	0.000223	0.00149	CcSEcCtD
Dronabinol—Musculoskeletal discomfort—Cyclosporine—psoriasis	0.000222	0.00149	CcSEcCtD
Dronabinol—CNR2—Signaling Pathways—HCAR2—psoriasis	0.000221	0.00443	CbGpPWpGaD
Dronabinol—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.00022	0.00441	CbGpPWpGaD
Dronabinol—Cough—Triamcinolone—psoriasis	0.000218	0.00146	CcSEcCtD
Dronabinol—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000217	0.00435	CbGpPWpGaD
Dronabinol—Somnolence—Cyclosporine—psoriasis	0.000217	0.00145	CcSEcCtD
Dronabinol—Musculoskeletal discomfort—Mycophenolate mofetil—psoriasis	0.000217	0.00145	CcSEcCtD
Dronabinol—Convulsion—Triamcinolone—psoriasis	0.000217	0.00145	CcSEcCtD
Dronabinol—Tachycardia—Prednisolone—psoriasis	0.000217	0.00145	CcSEcCtD
Dronabinol—Asthenia—Mycophenolic acid—psoriasis	0.000217	0.00145	CcSEcCtD
Dronabinol—Hyperhidrosis—Prednisolone—psoriasis	0.000215	0.00144	CcSEcCtD
Dronabinol—CNR2—GPCR downstream signaling—CCL20—psoriasis	0.000214	0.00429	CbGpPWpGaD
Dronabinol—Pruritus—Mycophenolic acid—psoriasis	0.000213	0.00143	CcSEcCtD
Dronabinol—Myalgia—Triamcinolone—psoriasis	0.000213	0.00143	CcSEcCtD
Dronabinol—Nervous system disorder—Hydrocortisone—psoriasis	0.000213	0.00143	CcSEcCtD
Dronabinol—PTGS1—Overview of nanoparticle effects—TNF—psoriasis	0.000212	0.00425	CbGpPWpGaD
Dronabinol—Decreased appetite—Cyclosporine—psoriasis	0.000212	0.00142	CcSEcCtD
Dronabinol—Tachycardia—Hydrocortisone—psoriasis	0.000212	0.00142	CcSEcCtD
Dronabinol—Somnolence—Mycophenolate mofetil—psoriasis	0.000212	0.00142	CcSEcCtD
Dronabinol—Drowsiness—Methotrexate—psoriasis	0.000212	0.00142	CcSEcCtD
Dronabinol—Depression—Methotrexate—psoriasis	0.000211	0.00141	CcSEcCtD
Dronabinol—Flushing—Prednisone—psoriasis	0.000211	0.00141	CcSEcCtD
Dronabinol—Skin disorder—Hydrocortisone—psoriasis	0.000211	0.00141	CcSEcCtD
Dronabinol—Ill-defined disorder—Betamethasone—psoriasis	0.000211	0.00141	CcSEcCtD
Dronabinol—Ill-defined disorder—Dexamethasone—psoriasis	0.000211	0.00141	CcSEcCtD
Dronabinol—Discomfort—Triamcinolone—psoriasis	0.000211	0.00141	CcSEcCtD
Dronabinol—Fatigue—Cyclosporine—psoriasis	0.00021	0.00141	CcSEcCtD
Dronabinol—Hyperhidrosis—Hydrocortisone—psoriasis	0.00021	0.00141	CcSEcCtD
Dronabinol—ABCB1—HIF-1-alpha transcription factor network—CP—psoriasis	0.000209	0.00419	CbGpPWpGaD
Dronabinol—Dry mouth—Triamcinolone—psoriasis	0.000208	0.0014	CcSEcCtD
Dronabinol—Decreased appetite—Mycophenolate mofetil—psoriasis	0.000207	0.00139	CcSEcCtD
Dronabinol—Anorexia—Hydrocortisone—psoriasis	0.000207	0.00139	CcSEcCtD
Dronabinol—Diarrhoea—Mycophenolic acid—psoriasis	0.000206	0.00138	CcSEcCtD
Dronabinol—Conjunctivitis—Methotrexate—psoriasis	0.000206	0.00138	CcSEcCtD
Dronabinol—Immune system disorder—Prednisone—psoriasis	0.000205	0.00138	CcSEcCtD
Dronabinol—CYP1A1—Tryptophan metabolism—CAT—psoriasis	0.000205	0.00411	CbGpPWpGaD
Dronabinol—Malaise—Dexamethasone—psoriasis	0.000205	0.00137	CcSEcCtD
Dronabinol—Malaise—Betamethasone—psoriasis	0.000205	0.00137	CcSEcCtD
Dronabinol—Sweating—Methotrexate—psoriasis	0.000203	0.00136	CcSEcCtD
Dronabinol—Hypotension—Hydrocortisone—psoriasis	0.000203	0.00136	CcSEcCtD
Dronabinol—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000203	0.00406	CbGpPWpGaD
Dronabinol—Feeling abnormal—Cyclosporine—psoriasis	0.000201	0.00135	CcSEcCtD
Dronabinol—Gastrointestinal pain—Cyclosporine—psoriasis	0.0002	0.00134	CcSEcCtD
Dronabinol—Dizziness—Mycophenolic acid—psoriasis	0.0002	0.00134	CcSEcCtD
Dronabinol—Tachycardia—Triamcinolone—psoriasis	0.000199	0.00134	CcSEcCtD
Dronabinol—Musculoskeletal discomfort—Hydrocortisone—psoriasis	0.000198	0.00133	CcSEcCtD
Dronabinol—Hyperhidrosis—Triamcinolone—psoriasis	0.000197	0.00132	CcSEcCtD
Dronabinol—Convulsion—Dexamethasone—psoriasis	0.000197	0.00132	CcSEcCtD
Dronabinol—Convulsion—Betamethasone—psoriasis	0.000197	0.00132	CcSEcCtD
Dronabinol—Feeling abnormal—Mycophenolate mofetil—psoriasis	0.000196	0.00132	CcSEcCtD
Dronabinol—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	0.000195	0.00131	CcSEcCtD
Dronabinol—CYP2C19—Biological oxidations—CYP2S1—psoriasis	0.000195	0.0039	CbGpPWpGaD
Dronabinol—CNR2—Signaling by GPCR—CCL20—psoriasis	0.000194	0.0039	CbGpPWpGaD
Dronabinol—Myalgia—Dexamethasone—psoriasis	0.000193	0.0013	CcSEcCtD
Dronabinol—Myalgia—Betamethasone—psoriasis	0.000193	0.0013	CcSEcCtD
Dronabinol—Abdominal pain—Cyclosporine—psoriasis	0.000193	0.00129	CcSEcCtD
Dronabinol—Anxiety—Dexamethasone—psoriasis	0.000193	0.00129	CcSEcCtD
Dronabinol—Anxiety—Betamethasone—psoriasis	0.000193	0.00129	CcSEcCtD
Dronabinol—CYP2C19—Metapathway biotransformation—CYP2S1—psoriasis	0.000192	0.00385	CbGpPWpGaD
Dronabinol—CNR2—Signaling Pathways—TAGAP—psoriasis	0.000192	0.00384	CbGpPWpGaD
Dronabinol—Discomfort—Betamethasone—psoriasis	0.000191	0.00128	CcSEcCtD
Dronabinol—Discomfort—Dexamethasone—psoriasis	0.000191	0.00128	CcSEcCtD
Dronabinol—Rash—Mycophenolic acid—psoriasis	0.00019	0.00128	CcSEcCtD
Dronabinol—Dermatitis—Mycophenolic acid—psoriasis	0.00019	0.00127	CcSEcCtD
Dronabinol—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000189	0.00379	CbGpPWpGaD
Dronabinol—Headache—Mycophenolic acid—psoriasis	0.000189	0.00127	CcSEcCtD
Dronabinol—Decreased appetite—Hydrocortisone—psoriasis	0.000189	0.00126	CcSEcCtD
Dronabinol—CYP2C19—Melatonin metabolism and effects—APOE—psoriasis	0.000189	0.00378	CbGpPWpGaD
Dronabinol—Abdominal pain—Mycophenolate mofetil—psoriasis	0.000188	0.00126	CcSEcCtD
Dronabinol—Fatigue—Hydrocortisone—psoriasis	0.000187	0.00125	CcSEcCtD
Dronabinol—Musculoskeletal discomfort—Triamcinolone—psoriasis	0.000186	0.00125	CcSEcCtD
Dronabinol—Ill-defined disorder—Prednisone—psoriasis	0.000184	0.00123	CcSEcCtD
Dronabinol—Feeling abnormal—Prednisolone—psoriasis	0.000183	0.00123	CcSEcCtD
Dronabinol—CNR1—BDNF signaling pathway—JUN—psoriasis	0.000182	0.00366	CbGpPWpGaD
Dronabinol—Nervous system disorder—Betamethasone—psoriasis	0.000182	0.00122	CcSEcCtD
Dronabinol—Nervous system disorder—Dexamethasone—psoriasis	0.000182	0.00122	CcSEcCtD
Dronabinol—Tachycardia—Betamethasone—psoriasis	0.000181	0.00121	CcSEcCtD
Dronabinol—Tachycardia—Dexamethasone—psoriasis	0.000181	0.00121	CcSEcCtD
Dronabinol—Hypersensitivity—Cyclosporine—psoriasis	0.00018	0.00121	CcSEcCtD
Dronabinol—Hyperhidrosis—Betamethasone—psoriasis	0.000179	0.0012	CcSEcCtD
Dronabinol—Hyperhidrosis—Dexamethasone—psoriasis	0.000179	0.0012	CcSEcCtD
Dronabinol—Feeling abnormal—Hydrocortisone—psoriasis	0.000179	0.0012	CcSEcCtD
Dronabinol—Malaise—Prednisone—psoriasis	0.000178	0.0012	CcSEcCtD
Dronabinol—CYP2A6—NRF2 pathway—TGFA—psoriasis	0.000178	0.00356	CbGpPWpGaD
Dronabinol—Gastrointestinal pain—Hydrocortisone—psoriasis	0.000177	0.00119	CcSEcCtD
Dronabinol—CYP2C9—Biological oxidations—CYP2S1—psoriasis	0.000177	0.00356	CbGpPWpGaD
Dronabinol—Tinnitus—Methotrexate—psoriasis	0.000177	0.00119	CcSEcCtD
Dronabinol—Anorexia—Dexamethasone—psoriasis	0.000177	0.00118	CcSEcCtD
Dronabinol—Anorexia—Betamethasone—psoriasis	0.000177	0.00118	CcSEcCtD
Dronabinol—ABCG2—HIF-1-alpha transcription factor network—LEP—psoriasis	0.000176	0.00353	CbGpPWpGaD
Dronabinol—Fatigue—Triamcinolone—psoriasis	0.000176	0.00118	CcSEcCtD
Dronabinol—CNR1—BDNF signaling pathway—NFKB1—psoriasis	0.000176	0.00352	CbGpPWpGaD
Dronabinol—Hypersensitivity—Mycophenolate mofetil—psoriasis	0.000175	0.00118	CcSEcCtD
Dronabinol—Asthenia—Cyclosporine—psoriasis	0.000175	0.00117	CcSEcCtD
Dronabinol—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	0.000175	0.00351	CbGpPWpGaD
Dronabinol—CNR1—Signaling Pathways—HCAR2—psoriasis	0.000174	0.00348	CbGpPWpGaD
Dronabinol—PTGS1—Selenium Micronutrient Network—CAT—psoriasis	0.000173	0.00347	CbGpPWpGaD
Dronabinol—Hypotension—Dexamethasone—psoriasis	0.000173	0.00116	CcSEcCtD
Dronabinol—Hypotension—Betamethasone—psoriasis	0.000173	0.00116	CcSEcCtD
Dronabinol—Pruritus—Cyclosporine—psoriasis	0.000173	0.00116	CcSEcCtD
Dronabinol—Immune system disorder—Methotrexate—psoriasis	0.000172	0.00115	CcSEcCtD
Dronabinol—Abdominal pain—Hydrocortisone—psoriasis	0.000172	0.00115	CcSEcCtD
Dronabinol—Convulsion—Prednisone—psoriasis	0.000171	0.00115	CcSEcCtD
Dronabinol—PTGS1—Overview of nanoparticle effects—IL6—psoriasis	0.000171	0.00343	CbGpPWpGaD
Dronabinol—Asthenia—Mycophenolate mofetil—psoriasis	0.000171	0.00115	CcSEcCtD
Dronabinol—Chills—Methotrexate—psoriasis	0.00017	0.00114	CcSEcCtD
Dronabinol—CNR2—G alpha (i) signalling events—CXCL8—psoriasis	0.000169	0.00339	CbGpPWpGaD
Dronabinol—Musculoskeletal discomfort—Betamethasone—psoriasis	0.000169	0.00113	CcSEcCtD
Dronabinol—Musculoskeletal discomfort—Dexamethasone—psoriasis	0.000169	0.00113	CcSEcCtD
Dronabinol—Pruritus—Mycophenolate mofetil—psoriasis	0.000168	0.00113	CcSEcCtD
Dronabinol—Myalgia—Prednisone—psoriasis	0.000168	0.00113	CcSEcCtD
Dronabinol—Feeling abnormal—Triamcinolone—psoriasis	0.000168	0.00113	CcSEcCtD
Dronabinol—CNR1—GPCR downstream signaling—CCL20—psoriasis	0.000168	0.00337	CbGpPWpGaD
Dronabinol—Anxiety—Prednisone—psoriasis	0.000168	0.00113	CcSEcCtD
Dronabinol—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	0.000167	0.00112	CcSEcCtD
Dronabinol—Diarrhoea—Cyclosporine—psoriasis	0.000167	0.00112	CcSEcCtD
Dronabinol—Discomfort—Prednisone—psoriasis	0.000166	0.00112	CcSEcCtD
Dronabinol—CYP1A1—PPARA activates gene expression—CARM1—psoriasis	0.000166	0.00333	CbGpPWpGaD
Dronabinol—ABCG2—HIF-1-alpha transcription factor network—NOS2—psoriasis	0.000164	0.00329	CbGpPWpGaD
Dronabinol—Hypersensitivity—Prednisolone—psoriasis	0.000164	0.0011	CcSEcCtD
Dronabinol—Diarrhoea—Mycophenolate mofetil—psoriasis	0.000163	0.00109	CcSEcCtD
Dronabinol—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CARM1—psoriasis	0.000162	0.00326	CbGpPWpGaD
Dronabinol—ABCG2—HIF-2-alpha transcription factor network—VEGFA—psoriasis	0.000162	0.00324	CbGpPWpGaD
Dronabinol—Dizziness—Cyclosporine—psoriasis	0.000161	0.00108	CcSEcCtD
Dronabinol—ABCB1—Allograft Rejection—HLA-C—psoriasis	0.000161	0.00324	CbGpPWpGaD
Dronabinol—Decreased appetite—Dexamethasone—psoriasis	0.000161	0.00108	CcSEcCtD
Dronabinol—Decreased appetite—Betamethasone—psoriasis	0.000161	0.00108	CcSEcCtD
Dronabinol—ABCB1—Allograft Rejection—IL13—psoriasis	0.00016	0.00322	CbGpPWpGaD
Dronabinol—Hypersensitivity—Hydrocortisone—psoriasis	0.00016	0.00107	CcSEcCtD
Dronabinol—Fatigue—Betamethasone—psoriasis	0.00016	0.00107	CcSEcCtD
Dronabinol—Fatigue—Dexamethasone—psoriasis	0.00016	0.00107	CcSEcCtD
Dronabinol—Nervous system disorder—Prednisone—psoriasis	0.000158	0.00106	CcSEcCtD
Dronabinol—CNR1—BDNF signaling pathway—STAT3—psoriasis	0.000158	0.00316	CbGpPWpGaD
Dronabinol—Tachycardia—Prednisone—psoriasis	0.000158	0.00106	CcSEcCtD
Dronabinol—Dizziness—Mycophenolate mofetil—psoriasis	0.000157	0.00106	CcSEcCtD
Dronabinol—Skin disorder—Prednisone—psoriasis	0.000157	0.00105	CcSEcCtD
Dronabinol—Hyperhidrosis—Prednisone—psoriasis	0.000156	0.00105	CcSEcCtD
Dronabinol—Asthenia—Hydrocortisone—psoriasis	0.000156	0.00104	CcSEcCtD
Dronabinol—Rash—Cyclosporine—psoriasis	0.000154	0.00103	CcSEcCtD
Dronabinol—Anorexia—Prednisone—psoriasis	0.000154	0.00103	CcSEcCtD
Dronabinol—Dermatitis—Cyclosporine—psoriasis	0.000154	0.00103	CcSEcCtD
Dronabinol—Pruritus—Hydrocortisone—psoriasis	0.000153	0.00103	CcSEcCtD
Dronabinol—Ill-defined disorder—Methotrexate—psoriasis	0.000153	0.00103	CcSEcCtD
Dronabinol—Headache—Cyclosporine—psoriasis	0.000153	0.00103	CcSEcCtD
Dronabinol—Feeling abnormal—Dexamethasone—psoriasis	0.000153	0.00102	CcSEcCtD
Dronabinol—Feeling abnormal—Betamethasone—psoriasis	0.000153	0.00102	CcSEcCtD
Dronabinol—CNR1—Signaling by GPCR—CCL20—psoriasis	0.000153	0.00306	CbGpPWpGaD
Dronabinol—Gastrointestinal pain—Dexamethasone—psoriasis	0.000152	0.00102	CcSEcCtD
Dronabinol—Gastrointestinal pain—Betamethasone—psoriasis	0.000152	0.00102	CcSEcCtD
Dronabinol—Hypersensitivity—Triamcinolone—psoriasis	0.000151	0.00101	CcSEcCtD
Dronabinol—CNR1—Signaling Pathways—TAGAP—psoriasis	0.00015	0.00302	CbGpPWpGaD
Dronabinol—Rash—Mycophenolate mofetil—psoriasis	0.00015	0.00101	CcSEcCtD
Dronabinol—Dermatitis—Mycophenolate mofetil—psoriasis	0.00015	0.00101	CcSEcCtD
Dronabinol—Headache—Mycophenolate mofetil—psoriasis	0.000149	0.001	CcSEcCtD
Dronabinol—Malaise—Methotrexate—psoriasis	0.000149	0.000999	CcSEcCtD
Dronabinol—Diarrhoea—Hydrocortisone—psoriasis	0.000148	0.000995	CcSEcCtD
Dronabinol—ABCB1—Allograft Rejection—IL17A—psoriasis	0.000148	0.00296	CbGpPWpGaD
Dronabinol—Musculoskeletal discomfort—Prednisone—psoriasis	0.000147	0.000986	CcSEcCtD
Dronabinol—Dizziness—Prednisolone—psoriasis	0.000147	0.000985	CcSEcCtD
Dronabinol—Asthenia—Triamcinolone—psoriasis	0.000147	0.000983	CcSEcCtD
Dronabinol—Abdominal pain—Dexamethasone—psoriasis	0.000147	0.000982	CcSEcCtD
Dronabinol—Abdominal pain—Betamethasone—psoriasis	0.000147	0.000982	CcSEcCtD
Dronabinol—Pruritus—Triamcinolone—psoriasis	0.000145	0.000969	CcSEcCtD
Dronabinol—Cough—Methotrexate—psoriasis	0.000144	0.000967	CcSEcCtD
Dronabinol—Dizziness—Hydrocortisone—psoriasis	0.000143	0.000962	CcSEcCtD
Dronabinol—Convulsion—Methotrexate—psoriasis	0.000143	0.00096	CcSEcCtD
Dronabinol—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000141	0.00283	CbGpPWpGaD
Dronabinol—Myalgia—Methotrexate—psoriasis	0.000141	0.000943	CcSEcCtD
Dronabinol—Decreased appetite—Prednisone—psoriasis	0.00014	0.000941	CcSEcCtD
Dronabinol—Rash—Prednisolone—psoriasis	0.00014	0.000939	CcSEcCtD
Dronabinol—Dermatitis—Prednisolone—psoriasis	0.00014	0.000938	CcSEcCtD
Dronabinol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	0.00014	0.000937	CcSEcCtD
Dronabinol—Fatigue—Prednisone—psoriasis	0.000139	0.000933	CcSEcCtD
Dronabinol—Headache—Prednisolone—psoriasis	0.000139	0.000933	CcSEcCtD
Dronabinol—Discomfort—Methotrexate—psoriasis	0.000139	0.000932	CcSEcCtD
Dronabinol—PTGS1—Selenium Micronutrient Network—CRP—psoriasis	0.000138	0.00276	CbGpPWpGaD
Dronabinol—ABCB1—Allograft Rejection—IL12B—psoriasis	0.000137	0.00275	CbGpPWpGaD
Dronabinol—CYP1A1—Melatonin metabolism and effects—NFKB1—psoriasis	0.000137	0.00275	CbGpPWpGaD
Dronabinol—Rash—Hydrocortisone—psoriasis	0.000137	0.000917	CcSEcCtD
Dronabinol—Dermatitis—Hydrocortisone—psoriasis	0.000137	0.000916	CcSEcCtD
Dronabinol—Confusional state—Methotrexate—psoriasis	0.000136	0.000912	CcSEcCtD
Dronabinol—Headache—Hydrocortisone—psoriasis	0.000136	0.000911	CcSEcCtD
Dronabinol—Dizziness—Triamcinolone—psoriasis	0.000135	0.000906	CcSEcCtD
Dronabinol—CNR2—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	0.000134	0.00269	CbGpPWpGaD
Dronabinol—ABCB1—Allograft Rejection—HLA-E—psoriasis	0.000134	0.00269	CbGpPWpGaD
Dronabinol—CYP1A1—Oxidative Stress—NFKB1—psoriasis	0.000133	0.00267	CbGpPWpGaD
Dronabinol—Feeling abnormal—Prednisone—psoriasis	0.000133	0.000892	CcSEcCtD
Dronabinol—Asthenia—Betamethasone—psoriasis	0.000133	0.000892	CcSEcCtD
Dronabinol—Asthenia—Dexamethasone—psoriasis	0.000133	0.000892	CcSEcCtD
Dronabinol—CNR1—G alpha (i) signalling events—CXCL8—psoriasis	0.000133	0.00266	CbGpPWpGaD
Dronabinol—Nervous system disorder—Methotrexate—psoriasis	0.000132	0.000887	CcSEcCtD
Dronabinol—Gastrointestinal pain—Prednisone—psoriasis	0.000132	0.000885	CcSEcCtD
Dronabinol—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000132	0.00264	CbGpPWpGaD
Dronabinol—Pruritus—Betamethasone—psoriasis	0.000131	0.000879	CcSEcCtD
Dronabinol—Pruritus—Dexamethasone—psoriasis	0.000131	0.000879	CcSEcCtD
Dronabinol—Skin disorder—Methotrexate—psoriasis	0.000131	0.000879	CcSEcCtD
Dronabinol—Hyperhidrosis—Methotrexate—psoriasis	0.00013	0.000874	CcSEcCtD
Dronabinol—Rash—Triamcinolone—psoriasis	0.000129	0.000864	CcSEcCtD
Dronabinol—Dermatitis—Triamcinolone—psoriasis	0.000129	0.000863	CcSEcCtD
Dronabinol—Anorexia—Methotrexate—psoriasis	0.000129	0.000862	CcSEcCtD
Dronabinol—Headache—Triamcinolone—psoriasis	0.000128	0.000858	CcSEcCtD
Dronabinol—Abdominal pain—Prednisone—psoriasis	0.000128	0.000856	CcSEcCtD
Dronabinol—Diarrhoea—Betamethasone—psoriasis	0.000127	0.00085	CcSEcCtD
Dronabinol—Diarrhoea—Dexamethasone—psoriasis	0.000127	0.00085	CcSEcCtD
Dronabinol—PTGS1—Selenium Micronutrient Network—ICAM1—psoriasis	0.000126	0.00253	CbGpPWpGaD
Dronabinol—Hypotension—Methotrexate—psoriasis	0.000126	0.000845	CcSEcCtD
Dronabinol—ABCG2—Fluoropyrimidine Activity—TP53—psoriasis	0.000125	0.00251	CbGpPWpGaD
Dronabinol—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000125	0.0025	CbGpPWpGaD
Dronabinol—Musculoskeletal discomfort—Methotrexate—psoriasis	0.000123	0.000824	CcSEcCtD
Dronabinol—Dizziness—Betamethasone—psoriasis	0.000123	0.000822	CcSEcCtD
Dronabinol—Dizziness—Dexamethasone—psoriasis	0.000123	0.000822	CcSEcCtD
Dronabinol—Somnolence—Methotrexate—psoriasis	0.00012	0.000804	CcSEcCtD
Dronabinol—Hypersensitivity—Prednisone—psoriasis	0.000119	0.000797	CcSEcCtD
Dronabinol—Decreased appetite—Methotrexate—psoriasis	0.000117	0.000786	CcSEcCtD
Dronabinol—CYP3A4—Biological oxidations—CYP2S1—psoriasis	0.000117	0.00234	CbGpPWpGaD
Dronabinol—Rash—Dexamethasone—psoriasis	0.000117	0.000784	CcSEcCtD
Dronabinol—Rash—Betamethasone—psoriasis	0.000117	0.000784	CcSEcCtD
Dronabinol—Dermatitis—Dexamethasone—psoriasis	0.000117	0.000783	CcSEcCtD
Dronabinol—Dermatitis—Betamethasone—psoriasis	0.000117	0.000783	CcSEcCtD
Dronabinol—Fatigue—Methotrexate—psoriasis	0.000116	0.00078	CcSEcCtD
Dronabinol—Headache—Betamethasone—psoriasis	0.000116	0.000779	CcSEcCtD
Dronabinol—Headache—Dexamethasone—psoriasis	0.000116	0.000779	CcSEcCtD
Dronabinol—Asthenia—Prednisone—psoriasis	0.000116	0.000776	CcSEcCtD
Dronabinol—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	0.000115	0.00231	CbGpPWpGaD
Dronabinol—CNR2—Signaling Pathways—CCL20—psoriasis	0.000115	0.0023	CbGpPWpGaD
Dronabinol—Pruritus—Prednisone—psoriasis	0.000114	0.000766	CcSEcCtD
Dronabinol—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	0.000114	0.00228	CbGpPWpGaD
Dronabinol—CYP2A6—Fluoropyrimidine Activity—TP53—psoriasis	0.000114	0.00228	CbGpPWpGaD
Dronabinol—CYP2C19—Melatonin metabolism and effects—NFKB1—psoriasis	0.000112	0.00225	CbGpPWpGaD
Dronabinol—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—CARM1—psoriasis	0.000112	0.00224	CbGpPWpGaD
Dronabinol—Feeling abnormal—Methotrexate—psoriasis	0.000111	0.000745	CcSEcCtD
Dronabinol—ABCB1—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	0.000111	0.00222	CbGpPWpGaD
Dronabinol—Diarrhoea—Prednisone—psoriasis	0.00011	0.00074	CcSEcCtD
Dronabinol—Gastrointestinal pain—Methotrexate—psoriasis	0.00011	0.00074	CcSEcCtD
Dronabinol—ABCG2—HIF-1-alpha transcription factor network—JUN—psoriasis	0.000109	0.00218	CbGpPWpGaD
Dronabinol—Dizziness—Prednisone—psoriasis	0.000107	0.000716	CcSEcCtD
Dronabinol—Abdominal pain—Methotrexate—psoriasis	0.000107	0.000715	CcSEcCtD
Dronabinol—CNR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	0.000105	0.00211	CbGpPWpGaD
Dronabinol—CNR2—GPCR ligand binding—CXCL8—psoriasis	0.000102	0.00205	CbGpPWpGaD
Dronabinol—Rash—Prednisone—psoriasis	0.000102	0.000682	CcSEcCtD
Dronabinol—Dermatitis—Prednisone—psoriasis	0.000102	0.000682	CcSEcCtD
Dronabinol—Headache—Prednisone—psoriasis	0.000101	0.000678	CcSEcCtD
Dronabinol—CYP3A4—Tryptophan metabolism—CAT—psoriasis	0.000101	0.00202	CbGpPWpGaD
Dronabinol—ABCB1—Allograft Rejection—IL10—psoriasis	0.0001	0.00201	CbGpPWpGaD
Dronabinol—Hypersensitivity—Methotrexate—psoriasis	9.94e-05	0.000666	CcSEcCtD
Dronabinol—CYP1A1—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	9.84e-05	0.00197	CbGpPWpGaD
Dronabinol—ABCB1—Allograft Rejection—IL4—psoriasis	9.76e-05	0.00196	CbGpPWpGaD
Dronabinol—Asthenia—Methotrexate—psoriasis	9.68e-05	0.000649	CcSEcCtD
Dronabinol—PTGS1—Selenium Micronutrient Network—IFNG—psoriasis	9.62e-05	0.00193	CbGpPWpGaD
Dronabinol—ABCB1—Allograft Rejection—HLA-B—psoriasis	9.55e-05	0.00191	CbGpPWpGaD
Dronabinol—Pruritus—Methotrexate—psoriasis	9.54e-05	0.00064	CcSEcCtD
Dronabinol—ABCB1—HIF-1-alpha transcription factor network—LEP—psoriasis	9.53e-05	0.00191	CbGpPWpGaD
Dronabinol—ABCG2—HIF-1-alpha transcription factor network—VEGFA—psoriasis	9.52e-05	0.00191	CbGpPWpGaD
Dronabinol—CYP1A1—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	9.48e-05	0.0019	CbGpPWpGaD
Dronabinol—Diarrhoea—Methotrexate—psoriasis	9.23e-05	0.000619	CcSEcCtD
Dronabinol—CNR1—Signaling Pathways—CCL20—psoriasis	9.01e-05	0.00181	CbGpPWpGaD
Dronabinol—Dizziness—Methotrexate—psoriasis	8.92e-05	0.000598	CcSEcCtD
Dronabinol—ABCB1—HIF-1-alpha transcription factor network—NOS2—psoriasis	8.88e-05	0.00178	CbGpPWpGaD
Dronabinol—ABCB1—Allograft Rejection—HLA-A—psoriasis	8.84e-05	0.00177	CbGpPWpGaD
Dronabinol—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	8.7e-05	0.00174	CbGpPWpGaD
Dronabinol—CYP1A1—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	8.6e-05	0.00172	CbGpPWpGaD
Dronabinol—Rash—Methotrexate—psoriasis	8.51e-05	0.00057	CcSEcCtD
Dronabinol—Dermatitis—Methotrexate—psoriasis	8.5e-05	0.00057	CcSEcCtD
Dronabinol—Headache—Methotrexate—psoriasis	8.45e-05	0.000567	CcSEcCtD
Dronabinol—ABCB1—Allograft Rejection—HLA-DRB1—psoriasis	8.08e-05	0.00162	CbGpPWpGaD
Dronabinol—CNR1—GPCR ligand binding—CXCL8—psoriasis	8.03e-05	0.00161	CbGpPWpGaD
Dronabinol—PTGS1—Selenium Micronutrient Network—NFKB1—psoriasis	8e-05	0.0016	CbGpPWpGaD
Dronabinol—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	7.37e-05	0.00148	CbGpPWpGaD
Dronabinol—CYP1A1—Aryl Hydrocarbon Receptor—TNF—psoriasis	7.37e-05	0.00148	CbGpPWpGaD
Dronabinol—ABCG2—Metabolism—NDUFA5—psoriasis	7.06e-05	0.00142	CbGpPWpGaD
Dronabinol—CYP1A1—PPARA activates gene expression—PPARG—psoriasis	6.91e-05	0.00139	CbGpPWpGaD
Dronabinol—PTGS1—Metabolism—NDUFA5—psoriasis	6.79e-05	0.00136	CbGpPWpGaD
Dronabinol—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—psoriasis	6.76e-05	0.00136	CbGpPWpGaD
Dronabinol—ABCG2—Transmembrane transport of small molecules—CP—psoriasis	6.56e-05	0.00132	CbGpPWpGaD
Dronabinol—CYP2A6—Metabolism—NDUFA5—psoriasis	6.42e-05	0.00129	CbGpPWpGaD
Dronabinol—PTGS1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	6.33e-05	0.00127	CbGpPWpGaD
Dronabinol—CNR2—Signaling Pathways—SOCS1—psoriasis	6.33e-05	0.00127	CbGpPWpGaD
Dronabinol—ABCG2—Transmembrane transport of small molecules—CARM1—psoriasis	6.26e-05	0.00126	CbGpPWpGaD
Dronabinol—PTGS1—Selenium Micronutrient Network—TNF—psoriasis	6.23e-05	0.00125	CbGpPWpGaD
Dronabinol—CNR2—Signaling by GPCR—TYK2—psoriasis	6.03e-05	0.00121	CbGpPWpGaD
Dronabinol—ABCG2—Metabolism—CYP2S1—psoriasis	6.01e-05	0.0012	CbGpPWpGaD
Dronabinol—ABCB1—Allograft Rejection—IFNG—psoriasis	5.9e-05	0.00118	CbGpPWpGaD
Dronabinol—ABCB1—HIF-1-alpha transcription factor network—JUN—psoriasis	5.89e-05	0.00118	CbGpPWpGaD
Dronabinol—CNR2—GPCR downstream signaling—CXCL8—psoriasis	5.78e-05	0.00116	CbGpPWpGaD
Dronabinol—PTGS1—Metabolism—CYP2S1—psoriasis	5.77e-05	0.00116	CbGpPWpGaD
Dronabinol—ABCB1—Allograft Rejection—CXCL8—psoriasis	5.49e-05	0.0011	CbGpPWpGaD
Dronabinol—CYP2A6—Metabolism—CYP2S1—psoriasis	5.46e-05	0.00109	CbGpPWpGaD
Dronabinol—CNR2—Signaling by GPCR—CXCL8—psoriasis	5.25e-05	0.00105	CbGpPWpGaD
Dronabinol—ABCB1—HIF-1-alpha transcription factor network—VEGFA—psoriasis	5.15e-05	0.00103	CbGpPWpGaD
Dronabinol—PTGS1—Selenium Micronutrient Network—IL6—psoriasis	5.02e-05	0.00101	CbGpPWpGaD
Dronabinol—CNR1—Signaling Pathways—SOCS1—psoriasis	4.96e-05	0.000995	CbGpPWpGaD
Dronabinol—CYP1A1—Metabolism—NDUFA5—psoriasis	4.78e-05	0.000958	CbGpPWpGaD
Dronabinol—CNR1—Signaling by GPCR—TYK2—psoriasis	4.73e-05	0.000949	CbGpPWpGaD
Dronabinol—CNR2—Signaling Pathways—LEP—psoriasis	4.67e-05	0.000936	CbGpPWpGaD
Dronabinol—CNR2—Signaling Pathways—APOE—psoriasis	4.67e-05	0.000936	CbGpPWpGaD
Dronabinol—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—psoriasis	4.66e-05	0.000934	CbGpPWpGaD
Dronabinol—CNR1—GPCR downstream signaling—CXCL8—psoriasis	4.54e-05	0.00091	CbGpPWpGaD
Dronabinol—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	4.52e-05	0.000906	CbGpPWpGaD
Dronabinol—CYP1A1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	4.46e-05	0.000894	CbGpPWpGaD
Dronabinol—ABCB1—Allograft Rejection—VEGFA—psoriasis	4.46e-05	0.000893	CbGpPWpGaD
Dronabinol—CNR2—Signaling Pathways—NFKBIA—psoriasis	4.35e-05	0.000872	CbGpPWpGaD
Dronabinol—CNR1—Signaling by GPCR—CXCL8—psoriasis	4.12e-05	0.000826	CbGpPWpGaD
Dronabinol—CYP1A1—Metabolism—CYP2S1—psoriasis	4.07e-05	0.000815	CbGpPWpGaD
Dronabinol—CYP2C19—Metabolism—NDUFA5—psoriasis	3.91e-05	0.000784	CbGpPWpGaD
Dronabinol—ABCB1—Allograft Rejection—TNF—psoriasis	3.82e-05	0.000766	CbGpPWpGaD
Dronabinol—ABCB1—Metabolism—NDUFA5—psoriasis	3.82e-05	0.000765	CbGpPWpGaD
Dronabinol—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	3.8e-05	0.000761	CbGpPWpGaD
Dronabinol—CNR1—Signaling Pathways—APOE—psoriasis	3.66e-05	0.000734	CbGpPWpGaD
Dronabinol—CNR1—Signaling Pathways—LEP—psoriasis	3.66e-05	0.000734	CbGpPWpGaD
Dronabinol—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.65e-05	0.000731	CbGpPWpGaD
Dronabinol—CYP2C9—Metabolism—NDUFA5—psoriasis	3.57e-05	0.000715	CbGpPWpGaD
Dronabinol—CNR2—Signaling Pathways—TYK2—psoriasis	3.56e-05	0.000714	CbGpPWpGaD
Dronabinol—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	3.55e-05	0.000711	CbGpPWpGaD
Dronabinol—CNR1—Signaling Pathways—NFKBIA—psoriasis	3.41e-05	0.000684	CbGpPWpGaD
Dronabinol—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	3.39e-05	0.000679	CbGpPWpGaD
Dronabinol—CYP2C19—Metabolism—CYP2S1—psoriasis	3.33e-05	0.000667	CbGpPWpGaD
Dronabinol—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.33e-05	0.000667	CbGpPWpGaD
Dronabinol—ABCB1—Metabolism—CYP2S1—psoriasis	3.25e-05	0.000651	CbGpPWpGaD
Dronabinol—CNR2—Signaling Pathways—CXCL8—psoriasis	3.1e-05	0.000622	CbGpPWpGaD
Dronabinol—CYP2C9—Metabolism—CYP2S1—psoriasis	3.03e-05	0.000608	CbGpPWpGaD
Dronabinol—PTGS1—Metabolism of lipids and lipoproteins—APOE—psoriasis	3.02e-05	0.000606	CbGpPWpGaD
Dronabinol—CNR2—Signaling by GPCR—IL6—psoriasis	2.95e-05	0.000591	CbGpPWpGaD
Dronabinol—ABCG2—Metabolism—CARM1—psoriasis	2.93e-05	0.000588	CbGpPWpGaD
Dronabinol—CNR2—Signaling Pathways—JUN—psoriasis	2.88e-05	0.000578	CbGpPWpGaD
Dronabinol—PTGS1—Metabolism—CARM1—psoriasis	2.82e-05	0.000565	CbGpPWpGaD
Dronabinol—CNR1—Signaling Pathways—TYK2—psoriasis	2.8e-05	0.00056	CbGpPWpGaD
Dronabinol—CNR2—Signaling Pathways—NFKB1—psoriasis	2.78e-05	0.000556	CbGpPWpGaD
Dronabinol—CYP2A6—Metabolism—CARM1—psoriasis	2.66e-05	0.000534	CbGpPWpGaD
Dronabinol—PTGS1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	2.63e-05	0.000528	CbGpPWpGaD
Dronabinol—CNR2—Signaling Pathways—VEGFA—psoriasis	2.52e-05	0.000505	CbGpPWpGaD
Dronabinol—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	2.52e-05	0.000505	CbGpPWpGaD
Dronabinol—CNR2—Signaling Pathways—STAT3—psoriasis	2.49e-05	0.0005	CbGpPWpGaD
Dronabinol—CNR1—Signaling Pathways—CXCL8—psoriasis	2.43e-05	0.000488	CbGpPWpGaD
Dronabinol—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	2.42e-05	0.000486	CbGpPWpGaD
Dronabinol—CYP3A4—Metabolism—NDUFA5—psoriasis	2.35e-05	0.000472	CbGpPWpGaD
Dronabinol—CNR1—Signaling by GPCR—IL6—psoriasis	2.31e-05	0.000464	CbGpPWpGaD
Dronabinol—CNR1—Signaling Pathways—JUN—psoriasis	2.26e-05	0.000454	CbGpPWpGaD
Dronabinol—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	2.2e-05	0.000441	CbGpPWpGaD
Dronabinol—CNR1—Signaling Pathways—NFKB1—psoriasis	2.18e-05	0.000437	CbGpPWpGaD
Dronabinol—CYP1A1—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.13e-05	0.000427	CbGpPWpGaD
Dronabinol—CYP3A4—Metabolism—CYP2S1—psoriasis	2e-05	0.000401	CbGpPWpGaD
Dronabinol—CYP1A1—Metabolism—CARM1—psoriasis	1.99e-05	0.000398	CbGpPWpGaD
Dronabinol—CNR1—Signaling Pathways—VEGFA—psoriasis	1.98e-05	0.000396	CbGpPWpGaD
Dronabinol—CNR1—Signaling Pathways—STAT3—psoriasis	1.96e-05	0.000392	CbGpPWpGaD
Dronabinol—CNR2—Signaling Pathways—TP53—psoriasis	1.9e-05	0.000382	CbGpPWpGaD
Dronabinol—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	1.88e-05	0.000378	CbGpPWpGaD
Dronabinol—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.86e-05	0.000372	CbGpPWpGaD
Dronabinol—ABCG2—Metabolism—CAT—psoriasis	1.8e-05	0.000362	CbGpPWpGaD
Dronabinol—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.74e-05	0.000349	CbGpPWpGaD
Dronabinol—CNR2—Signaling Pathways—IL6—psoriasis	1.74e-05	0.000349	CbGpPWpGaD
Dronabinol—PTGS1—Metabolism—CAT—psoriasis	1.73e-05	0.000347	CbGpPWpGaD
Dronabinol—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.66e-05	0.000333	CbGpPWpGaD
Dronabinol—CYP2A6—Metabolism—CAT—psoriasis	1.64e-05	0.000329	CbGpPWpGaD
Dronabinol—CYP2C19—Metabolism—CARM1—psoriasis	1.62e-05	0.000326	CbGpPWpGaD
Dronabinol—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.59e-05	0.000319	CbGpPWpGaD
Dronabinol—ABCB1—Metabolism—CARM1—psoriasis	1.59e-05	0.000318	CbGpPWpGaD
Dronabinol—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.52e-05	0.000304	CbGpPWpGaD
Dronabinol—CNR1—Signaling Pathways—TP53—psoriasis	1.49e-05	0.000299	CbGpPWpGaD
Dronabinol—CYP2C9—Metabolism—CARM1—psoriasis	1.48e-05	0.000297	CbGpPWpGaD
Dronabinol—ABCG2—Metabolism—APOE—psoriasis	1.4e-05	0.000281	CbGpPWpGaD
Dronabinol—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.38e-05	0.000278	CbGpPWpGaD
Dronabinol—CNR1—Signaling Pathways—IL6—psoriasis	1.37e-05	0.000274	CbGpPWpGaD
Dronabinol—PTGS1—Metabolism—APOE—psoriasis	1.35e-05	0.00027	CbGpPWpGaD
Dronabinol—CYP2A6—Metabolism—APOE—psoriasis	1.27e-05	0.000255	CbGpPWpGaD
Dronabinol—CYP1A1—Metabolism—CAT—psoriasis	1.22e-05	0.000245	CbGpPWpGaD
Dronabinol—ABCG2—Metabolism—PPARG—psoriasis	1.22e-05	0.000245	CbGpPWpGaD
Dronabinol—PTGS1—Metabolism—PPARG—psoriasis	1.17e-05	0.000235	CbGpPWpGaD
Dronabinol—CYP2A6—Metabolism—PPARG—psoriasis	1.11e-05	0.000222	CbGpPWpGaD
Dronabinol—CYP2C19—Metabolism—CAT—psoriasis	9.99e-06	0.0002	CbGpPWpGaD
Dronabinol—CYP3A4—Metabolism—CARM1—psoriasis	9.77e-06	0.000196	CbGpPWpGaD
Dronabinol—ABCB1—Metabolism—CAT—psoriasis	9.75e-06	0.000195	CbGpPWpGaD
Dronabinol—CYP1A1—Metabolism—APOE—psoriasis	9.49e-06	0.00019	CbGpPWpGaD
Dronabinol—CYP2C9—Metabolism—CAT—psoriasis	9.11e-06	0.000183	CbGpPWpGaD
Dronabinol—CYP1A1—Metabolism—PPARG—psoriasis	8.26e-06	0.000166	CbGpPWpGaD
Dronabinol—CYP2C19—Metabolism—APOE—psoriasis	7.76e-06	0.000156	CbGpPWpGaD
Dronabinol—ABCB1—Metabolism—APOE—psoriasis	7.58e-06	0.000152	CbGpPWpGaD
Dronabinol—CYP2C9—Metabolism—APOE—psoriasis	7.08e-06	0.000142	CbGpPWpGaD
Dronabinol—CYP2C19—Metabolism—PPARG—psoriasis	6.76e-06	0.000136	CbGpPWpGaD
Dronabinol—ABCB1—Metabolism—PPARG—psoriasis	6.6e-06	0.000132	CbGpPWpGaD
Dronabinol—CYP2C9—Metabolism—PPARG—psoriasis	6.17e-06	0.000124	CbGpPWpGaD
Dronabinol—CYP3A4—Metabolism—CAT—psoriasis	6.01e-06	0.00012	CbGpPWpGaD
Dronabinol—CYP3A4—Metabolism—APOE—psoriasis	4.67e-06	9.36e-05	CbGpPWpGaD
Dronabinol—CYP3A4—Metabolism—PPARG—psoriasis	4.07e-06	8.15e-05	CbGpPWpGaD
